Anti-angiogenic drugs target various receptors such as vascular endothelial growth factor receptor, platelet-derived growth factor receptor and fibroblast growth factor receptor (VEGFR, PDGFR, and FGFR), along with their downstream signaling pathways, to impede tumor angiogenesis. The gene discussed is KDR; the disease is neoplasm.